Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $80.00 Average PT from Analysts

Seres Therapeutics, Inc. (NASDAQ:MCRB) has earned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $80.00.

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 1st. The Goldman Sachs Group reduced their price objective on Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating for the company in a research report on Friday, March 14th. Finally, Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Seres Therapeutics in a research report on Thursday, March 20th.

Seres Therapeutics Stock Down 4.2 %

Seres Therapeutics stock opened at $9.23 on Friday. The company has a 50 day moving average of $12.22 and a 200-day moving average of $14.87. Seres Therapeutics has a twelve month low of $7.18 and a twelve month high of $30.60. The stock has a market capitalization of $80.47 million, a PE ratio of -40.13 and a beta of 2.89.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC boosted its position in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 28,500 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares in the last quarter. State Street Corp increased its holdings in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares during the last quarter. Finally, Northern Trust Corp raised its position in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 44,461 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.